



Marksans Pharma Ltd.

9th December, 2021

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: **MARKSANS**

To,
BSE Limited
P. J. Towers
Dalal Street
Mumbai – 400 001

Scrip Code: **524404**

PRESS RELEASE

Marksans Pharma Limited announces UK MHRA approval for Loperamide 2mg Hard Capsules.

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that UK MHRA has granted Market Authorisation to the Company's wholly owned subsidiary Relonchem Limited for Loperamide 2mg Hard Capsules.

Marksans will manufacture the products at its UK MHRA approved state-of-the-art oral dosage facility located at Goa, India.

For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91.22 4001 2000 • E-mail: info@marksanspharma.com
www.marksanspharma.com